Revivicor, Inc.
Records under this name other than the patents Revivicor, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 7 patents it holds.
Showing 1 to 10 of 10 · Back to Revivicor, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,300,112 | Transgenic ungulates expressing CTLA4-IG and uses thereof Term ended Term ended Aug 9, 2026 · From the USPTO record | Term ended | Term ended Aug 9, 2026 | From the USPTO record |
| US 7,795,493 | Porcine Animals Lacking Any Expression of Functional Alpha 1, 3 Galactosyltransferase Term ended Term ended May 13, 2026 · High confidence | Term ended | Term ended May 13, 2026 | High confidence |
| US 9,585,374 | Ungulates with genetically modified immune systems Term ended Term ended Oct 24, 2025 · From the USPTO record | Term ended | Term ended Oct 24, 2025 | From the USPTO record |
| US 11,085,054 | Ungulates with genetically modified immune systems Term ended Term ended Oct 24, 2025 · From the USPTO record | Term ended | Term ended Oct 24, 2025 | From the USPTO record |
| US 10,793,873 | Use of interfering RNA in the production of transgenic animals Lapsed on the fee record Ended Oct 6, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 6, 2024 | From the USPTO record |
| US 11,172,658 | Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase Term ended Term ended Dec 17, 2023 · From the USPTO record | Term ended | Term ended Dec 17, 2023 | From the USPTO record |
| US 10,912,863 | Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase Term ended Term ended Nov 23, 2023 · From the USPTO record | Term ended | Term ended Nov 23, 2023 | From the USPTO record |
| US 8,106,251 | Tissue Products Derived from Porcine Animals Lacking Any Expression of Functional Alpha 1,3 Galactosyltransferase Term ended Term ended Aug 21, 2023 · High confidence | Term ended | Term ended Aug 21, 2023 | High confidence |
| US 10,130,737 | Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase Term ended Ended no later than Aug 21, 2023 · From the USPTO record | Term ended | Ended no later than Aug 21, 2023 | From the USPTO record |
| US 7,531,715 | Double nuclear transfer method and results thereof Term ended Term ended Jan 13, 2020 · From the USPTO record | Term ended | Term ended Jan 13, 2020 | From the USPTO record |